Physician profile
Ira Fine
NPI 1922079599
$2,655.23
in general payments reported to CMS, 2019-2025
23 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.84 · 2020: $22.56 · 2021: $26.73 · 2022: $34.77 · 2023: $639 · 2024: $825 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $426.31 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $372.79 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $361.99 | 2023-2025 | |
| Amgen INC. | $251.78 | 2022-2025 | Evenity, Tavneos, Prolia |
| Janssen Biotech, INC. | $162.58 | 2019-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $148.94 | 2023-2025 | Idacio |
| Aurinia Pharma U.S., INC. | $138.80 | 2023-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $137.96 | 2023-2025 | Orencia |
| Sandoz INC. | $88.38 | 2023-2025 | Hyrimoz |
| Sobi, INC | $72.60 | 2024-2025 | |
| Genentech USA, INC. | $66.63 | 2025 | Actemra, Gazyva |
| Abbvie INC. | $59.44 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $59.08 | 2024-2025 | Capvaxive |
| Biocon Biologics INC | $51.91 | 2024 | Hulio |
| Alexion Pharmaceuticals, INC. | $43.18 | 2023-2025 | Strensiq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $37.23 | 2023 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $34.53 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $31.03 | 2025 | Benlysta |
| Kiniksa Pharmaceuticals International, Plc | $27.36 | 2024 | Arcalyst |
| Corcept Therapeutics | $23.67 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $23.12 | 2025 | Inspire |
| Kyowa Kirin, INC. | $18.36 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.